权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Use of lingual organoids to screen for the impact of targeted cancer therapies on taste bud renewal

使用舌类器官筛选靶向癌症疗法对味蕾更新的影响

基本信息

批准号：
9982260
负责人：
Linda A Barlow
金额：
$ 20.29万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9982260
关键词：
Adult Affect Animal Model Antibodies Antineoplastic Agents Attention BAY 54-9085 Biological Biological Assay Cancer Patient Cell Death Cell Differentiation process Cell Survival Cells Clinical Collection Confocal Microscopy Consumption Data Dental Hygiene Diet Modification Drug usage Dysgeusia Eating Epithelial Epithelial Cells Epithelium Functional disorder Future Goals Growth Harvest Homeostasis In Vitro Intervention Letters Malignant - descriptor Malignant Neoplasms Malignant neoplasm of kidney Mediating Metastatic Renal Cell Cancer Methodology Methods Molecular Monitor Mus Organoids Outcome Patients Pharmaceutical Preparations Phosphorylation Prevalence Process Proteome Proto-Oncogene Protein c-kit Publishing Quality of life RNA RNA Sequences Receptor Cell Receptor Protein-Tyrosine Kinases Renal Cell Carcinoma Reporter Reporting Role Sodium Chloride Sum Surface Symptoms Taste Bud Cell Taste Buds Taste Perception Technology Testing Therapeutic Uses Time Tongue Toxic effect Tyrosine Kinase Inhibitor Vascular Endothelial Growth Factor Receptor-1 Work automated image analysis cancer cell cancer therapy cell type cytotoxicity detector experience in vivo keratinocyte mouse model patient population progenitor regenerative response screening self-renewal sensory system side effect stem stem cells targeted cancer therapy time use tongue papilla transcriptome transcriptomics tumor tumor growth tumor progression

项目摘要

PROJECT SUMMARY Taste buds are composed of a heterogeneous collection of taste receptor cells (TRCs) that are continually renewed. Likely because of this regenerative capacity, taste distortion or dysgeusia is a common side effect of many anti-cancer drugs used to treat a host of malignancies. Crucially, patients report loss of taste as an extremely disruptive aspect of cancer treatment, dramatically affecting their quality of life and clinical outcomes. Current interventions for taste loss are minimally effective and consist primarily of dietary modifications and attention to oral hygiene. Here, we submit a revised proposal in response to PA-16-258 Mechanisms of Cancer and Treatment-related Symptoms and Toxicities, with the explicit rationale that understanding how cancer drugs impact taste homeostasis will generate future approaches to ameliorate taste dysfunction for cancer patients. Although a host of cancer drugs cause dysgeusia, we focus on a specific patient population, those suffering from malignant renal cell carcinoma (mRCC), treated with a one or more of 6 specific tyrosine kinase inhibitors (TKIs) used to inhibit receptor tyrosine kinases (RTKs) critical to tumor growth, i.e., VEGFR1-3 and PDGFRb. Importantly, these drugs, sunitinib, pazopanib, axitinib, cabozantinib, lenvatinib, and sorafenib, cause significant and troubling taste distortion for patients. However, how these drugs perturb taste is completely unknown. Intriguingly, interrogating both our own and published RNA sequence data reveals that neither VEGFR1-3 nor PDGFRb are expressed in taste epithelium. However, these TKIs also inhibit numerous other unintended RTKs including PDGFRa, c-Kit and Ret, which are expressed in taste epithelium, whose functions in mRCC are less essential, and whose roles in taste bud homeostasis are little explored. Thus, it is entirely plausible that TKIs used to treat mRCC act on intended VEGFR1-3 and PDGFRb to slow tumor progression, while in taste epithelium unintended RTKs are inhibited causing dysgeusia, thus providing us with a potential future avenue to mitigate taste dysfunction without interfering with cancer therapy. To assess how these targeted TKIs impact taste cell renewal, rather than using time-consuming and expensive mouse models, we propose to use cutting edge lingual organoid technology to rapidly and inexpensively screen for the effect of these drugs on discrete aspects of taste cell renewal. Our explicit hypothesis is that: TKIs used to treat mRCC affect discrete aspects of taste bud cell renewal, and act on RTKs expressed in taste epithelium that are distinct from their anti-tumor targets. This will be tested in 3 aims: Do mRCC TKIs affect activity and/or survival of taste bud progenitor cells (Aim 1); and/or differentiation of all or distinct subsets of TRCs (Aim 2); and which RTKs are inhibited in taste epithelium by TKIs used to treat mRCC patients (Aim 3).

项目总结